- Home
- SSM vs PULM Comparison
SSM vs PULM Comparison
Compare SSM & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SSM | PULM |
|---|---|---|
| Founded | N/A | 2003 |
| Country | Germany | United States |
| Employees | 43 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4M | 9.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SSM | PULM |
|---|---|---|
| Price | $6.77 | $2.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | ★ 13.1K |
| Earning Date | N/A | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $134.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | N/A | $2.15 |
| 52 Week High | N/A | $10.40 |
Technical Indicators
Market Signals| Indicator | SSM | PULM |
|---|---|---|
| Relative Strength Index (RSI) | 50.64 | 39.74 |
| Support Level | $6.72 | $2.47 |
| Resistance Level | $7.45 | $2.68 |
| Average True Range (ATR) | 0.36 | 0.18 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 35.14 | 10.00 |
Price Performance
Historical ComparisonAbout SSM Sono Group N.V. Ordinary Shares
Sono Group NV is engaged in the field of solar-powered electric mobility. With its proprietary solar technology, the company is able to integrate solar panels into a vehicle's bodywork, using energy captured from the sun to charge the vehicle's battery. The group is engaged in the design and development of its own first solar electric vehicle, the Sion. Its Products and Services includes Complete Solar Solutions, Solar Charge Controllers, Solar Modules, and Data Services and Engineering Services.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).